Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.67 |
| ▸ | RARG | P13631 | 17/20 | 0.67 |
| ▸ | RARA | P10276 | 14/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.50 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.45 |
| ▸ | RXRB | P28702 | 3/20 | 0.45 |
| ▸ | RXRG | P48443 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656647 | 1.00 | RARB (0.67) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL8657242 | 0.83 | RARA (0.50) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL3453631 | 0.81 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL31266609 | 0.81 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL8658266 | 0.78 | RARB (0.65) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL6378961 | 0.78 | RARB (0.61) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL5846371 | 0.78 | RARB (0.65) | RARBRARGRARARXRARXRB | |
| SCHEMBL8657215 | 0.76 | MEN1 (0.72) | RARBRARGRARA | |
| SCHEMBL9374463 | 0.75 | RARA (0.90) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL8659574 | 0.75 | RARB (0.63) | RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250345316-A1 | METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| EP-4430163-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240294879-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-09-05 | — | — | US | claimed |
| EP-4334436-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Yeda Research and Development Co. Ltd (IL) | 2024-03-13 | — | — | EP | claimed |
| US-20240074473-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-07 | — | — | US | claimed |
| EP-4304617-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | Vertex Pharmaceuticals Incorporated (US) | 2024-01-17 | — | — | EP | claimed |
| CN-116981466-A | Stem cell differentiation and polymers | 沃泰克斯药物股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2022234586-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-11-10 | — | — | WO | claimed |
| WO-2022192300-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-09-15 | — | — | WO | claimed |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2022026932-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | IAPP, CBX6, HLA-C | RARB 1354/4885RARG 584/4885RARA 1440/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | RARB 156/4885RARG 186/4885RARA 422/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARB 70/4885RARG 134/4885RARA 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.